Get the Stockscreener App
9.94
1.00%
-0.10
Contineum Therapeutics Inc stock is traded at $9.94, with a volume of 213.96K.
It is down -1.00% in the last 24 hours and up +91.89% over the past month.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
See More
Previous Close:
$10.04
Open:
$10.24
24h Volume:
213.96K
Relative Volume:
0.97
Market Cap:
$214.95M
Revenue:
-
Net Income/Loss:
$-35.46M
P/E Ratio:
-23.57
EPS:
-0.4218
Net Cash Flow:
$-34.00M
1W Performance:
+34.69%
1M Performance:
+91.89%
6M Performance:
+30.96%
1Y Performance:
-45.50%
1-Day Range:
$9.83
$10.67
1-Week Range:
$7.2601
$10.67
52-Week Range:
$3.35
$20.55
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
9.94 | 227.14M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-20-25 | Initiated | William Blair | Outperform |
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
Contineum Therapeutics Inc Stock (CTNM) Latest News
Chart based analysis of Contineum Therapeutics Inc. trendsWeekly Trend Report & Consistent Income Trade Ideas - Newser
How high can Contineum Therapeutics Inc. stock goWeekly Volume Report & Daily Profit Focused Screening - Newser
Developing predictive dashboards with Contineum Therapeutics Inc. dataQuarterly Growth Report & Daily Momentum Trading Reports - Newser
What indicators show strength in Contineum Therapeutics Inc.Portfolio Value Summary & Consistent Income Trade Recommendations - Newser
Will Contineum Therapeutics Inc. see short term momentumInflation Watch & Low Risk High Win Rate Picks - Newser
Contineum Therapeutics Inc. stock prediction for this weekFed Meeting & Weekly High Potential Stock Alerts - Newser
Contineum Therapeutics Inc. Stock Performance After Earnings: Historical InsightsJuly 2025 Breakouts & AI Optimized Trade Strategies - Newser
Using flow based indicators on Contineum Therapeutics Inc.CEO Change & Consistent Profit Trade Alerts - Newser
Can Contineum Therapeutics Inc. rally from current levels2025 Short Interest & Safe Swing Trade Setup Alerts - Newser
Price momentum metrics for Contineum Therapeutics Inc. explainedDay Trade & Weekly Market Pulse Updates - Newser
Morgan Stanley Issues Positive Forecast for Contineum Therapeutics (NASDAQ:CTNM) Stock Price - Defense World
What makes Contineum Therapeutics Inc. stock price move sharplyOptions Play & Precise Trade Entry Recommendations - Newser
Measuring Contineum Therapeutics Inc.’s beta against major indicesWeekly Profit Recap & Reliable Volume Spike Trade Alerts - Newser
What machine learning models say about Contineum Therapeutics Inc.2025 Retail Activity & Real-Time Volume Analysis - Newser
How Contineum Therapeutics Inc. stock reacts to Fed policy changesJuly 2025 News Drivers & Safe Swing Trade Setup Alerts - Newser
Is Contineum Therapeutics Inc. stock entering bullish territoryJuly 2025 Snapshot & Daily Profit Focused Screening - Newser
Using portfolio simulators with Contineum Therapeutics Inc. included2025 Price Action Summary & AI Driven Price Forecasts - Newser
How to use a screener to detect Contineum Therapeutics Inc. breakouts2025 Big Picture & Technical Buy Zone Confirmations - Newser
Contineum Therapeutics Reports Q2 2025 Results and Clinical Progress - MSN
Strategies to average down on Contineum Therapeutics Inc.2025 Market Sentiment & Breakout Confirmation Alerts - Newser
What data driven models say about Contineum Therapeutics Inc.’s futureJuly 2025 Setups & Expert Verified Stock Movement Alerts - Newser
Contineum Therapeutics Inc. Tests 50 Day MA After Sharp Decline2025 Key Lessons & Community Shared Stock Ideas - sundaytimes.kr
Earnings visualization tools for Contineum Therapeutics Inc.Earnings Overview Report & Free Technical Pattern Based Buy Signals - Newser
Contineum Therapeutics Inc. Attempts Reversal From Key SupportBond Market & Weekly Top Gainers Alerts - thegnnews.com
Has Contineum Therapeutics Inc. Stock Ever Crashed Historical Volatility Review2025 Breakouts & Breakdowns & Intraday High Probability Alerts - Newser
Chartists Watching For Breakout in Contineum Therapeutics Inc.2025 Macro Impact & Risk Adjusted Swing Trade Ideas - beatles.ru
Contineum Therapeutics Inc. Building a Base Near SupportPortfolio Value Report & Reliable Price Breakout Signals - newsyoung.net
Contineum Therapeutics Inc. stock trend forecastWeekly Stock Summary & Long-Term Growth Stock Strategies - Newser
Contineum Therapeutics shares fall 1.04% intraday after ORIC Pharmaceuticals reports positive clinical data and financing activity. - AInvest
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Contineum Therapeutics Inc Stock (CTNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lorrain Daniel S. | Chief Scientific Officer |
Nov 18 '24 |
Sale |
16.38 |
6,190 |
101,421 |
169,572 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):